Time required to achieve optimum viral load suppression with Ravidasvir/sofosbuvir in chronic hepatitis C patients with or without compensated cirrhosis

TL;DR

This study examines how quickly a drug combination suppresses hepatitis C virus in patients with or without liver damage.

Contribution

It identifies the time to achieve optimal viral load suppression in chronic hepatitis C patients with or without compensated cirrhosis.

Findings

Noncirrhotic patients achieved optimal viral suppression faster than cirrhotic patients.

80.6% of noncirrhotic patients achieved suppression within 4 weeks, and 92.6% within 8 weeks.

76.1% of cirrhotic patients achieved suppression within 4 weeks, and 90.4% within 8 weeks.

Abstract

A study indicated that ravidasvir (RDV) has excellent safety and tolerability when used with sofosbuvir (SOF) to treat chronic HCV infection. The aim of this study was to determine the time taken by RDV/SOF to achieve optimum viral load suppression in chronic hepatitis C patients with or without compensated cirrhosis. Data from the open-label, multicentre, single-arm, phase II/III clinical trial (STORM-C-1) were utilized. Time‒to-event analysis via Kaplan–Meier curves was performed to determine the time required to achieve optimum viral load suppression in both the cirrhotic and noncirrhotic groups. Multivariate logistic regression analyses were performed to identify potential predictors of achieving suppression within four and eight weeks. The time to achieve optimum viral load suppression ranged from six to 85 days and from five to 148 days among noncirrhotic and cirrhotic patients, respectively. Among noncirrhotic patients, 80.6% achieved optimum viral load suppression within 4 weeks, and 92.6% achieved this within 8 weeks. Among cirrhotic patients, 76.1% and 90.4% achieved optimum viral load suppression within 4 and 8 weeks, respectively. Notably, optimum viral load suppression differs from sustained virological response (SVR12), which is defined as undetectable HCV RNA 12 weeks after treatment completion. While the study demonstrates promising early viral suppression, it does not evaluate the efficacy of a shortened regimen. Further research is needed to assess whether shorter treatment durations maintain high SVR12 rates without compromising treatment success.

Figures